Virax Biolabs Group Limited Ordinary Shares

Virax Biolabs Group Limited, a biotechnology company, focuses on immune response detection, T cell immune profiling, and the development of in vitro diagnostic technologies for viral and immune-mediated diseases in the United Kingdom, the United States, and China. The company offers ViraxImmune, a T cell-based immune profiling and diagnostic platform for post-acute infection syndromes, including long COVID, myalgic encephalomyelitis / chronic fatigue syndrome, and post-treatment Lyme disease. It also provides ImmuneSelect, a research-use-only portfolio of peptide pool ELISpot plates and related immune reagents. In addition, the company is involved in research and development activities and the provision of procurement, warehousing, product development, and staffing management services. It serves research organizations, academic institutions, contract research organizations, biopharmaceutical companies, independent laboratories, and distributors. The company was formerly known as Virax Biolabs (Cayman) Limited and changed its name to Virax Biolabs Group Limited in September 2021. Virax Biolabs Group Limited was founded in 2013 and is headquartered in Lanarkshire, United Kingdom.